search
Back to results

Prevention and Treatment of Diabetes in Adults

Primary Purpose

PreDiabetes

Status
Recruiting
Phase
Not Applicable
Locations
Malaysia
Study Type
Interventional
Intervention
Mobile health
Usual care
Sponsored by
Monash University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for PreDiabetes focused on measuring digital health, mobile health, lifestyle program

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Aged 18 years and above
  • BMI 23 and above
  • HbA1c 5.7 - 6.4% or FPG 5.6mmol/L - 6.9mmol/L

Exclusion Criteria:

  • Unable to give informed consent
  • Pregnant or lactating
  • Established diabetes
  • Terminal illness
  • Does not own a mobile phone
  • Plans to relocate to an area or travel plans that do not permit full participation in the study

Sites / Locations

  • Shaun LeeRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Intervention arm

Usual care arm

Arm Description

Participants receiving the phone app together with a fitness tracker. All participants will receive the educational curriculum through the app over a period of 24 weeks. The mobile app allows secure patient monitoring through a participant dashboard that the coach can use to increase patient adherence and motivation to achieve goals. The participants can use the app to log their food intake, weight, steps, exercise, in addition to participating in the peer support via the chat function. Participants will also receive regular care and follow up in community pharmacies for support.

The control group will be a "usual care" condition in which participants are free to seek any assistance for their medical care during the study period. Participants will be given physical tracking sheets to record their food intake, weight, steps and exercises.

Outcomes

Primary Outcome Measures

Change in body weight
Weight Loss by % of change and total weight change (kg)

Secondary Outcome Measures

Incidence of diabetes
Number of participants who develop diabetes after 12 months
Change in hemoglobin A1c
Haemoglobin A1c measured during follow-up appointments
Change in health related quality of life
EuroQol (EQ-5D-5L) to assess quality of life, with higher scores indicating better quality of life. Hospital Anxiety Depression Scale, Perceived Stress Scale and Brief Illness Perception Questionnaire to access mood and mental health.
Change in dietary practice
3-day diet recall to assess changes in food intake
Change in physical activity
Physical Activity Questionnaire (short form) (IPAQ) to obtain internationally comparable data on health-related physical activity
Change in cardiovascular risks
Blood pressure and lipid profile will be collected to assess cardiovascular risks.
Change in anthropometry measures
Body fat composition in % change, and change in waist-to-hip ratio.

Full Information

First Posted
April 3, 2021
Last Updated
June 13, 2022
Sponsor
Monash University
Collaborators
Caring Pharmacy, Bionime Corporation, Tigas Pharma
search

1. Study Identification

Unique Protocol Identification Number
NCT04832984
Brief Title
Prevention and Treatment of Diabetes in Adults
Official Title
Addressing Disparity in Diabetes Prevention Through Digital Health Supported PRe-diabetes Intervention, Management and Evaluation (PRIME) Program Based in Malaysian Community Pharmacies
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Recruiting
Study Start Date
March 23, 2022 (Actual)
Primary Completion Date
June 30, 2024 (Anticipated)
Study Completion Date
June 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Monash University
Collaborators
Caring Pharmacy, Bionime Corporation, Tigas Pharma

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Currently, an estimated 3.9 million Malaysians continue to live with diabetes with many more who live with prediabetes. Diabetes was the one of the leading causes of death in the Malaysia and the leading cause for kidney failure, lower-limb amputations, and adult-onset blindness. Heart disease and stroke are two to four times more likely for individuals with diabetes. The use of mHealth or mobile health application can reduce blood sugar among individuals with prediabetes but also prevent a later occurrence of diabetes. In this study, the investigators aim to develop and evaluate the effectiveness of a digital health supported pre-diabetes management program based in an urban community pharmacy setting
Detailed Description
Pre-diabetes is an intermediate state of hyperglycaemia with glycaemic parameters above normal but below the type 2 diabetes mellitus (T2DM) threshold. It was estimated that >25% of individuals who are pre-diabetic convert to T2DM within 3-5 years and 70% of individuals with pre-diabetes will develop into full-fledge T2DM within their lifetimes. According to the 2017 estimate, the disease burden of pre-diabetes at Western Pacific region was 7.6% (126.7 millions). The situation is more alarming in Malaysia where a national pre-diabetes prevalence of 22.1% was noted. Currently available support and self-care services offered in Public Hospitals such as the Diabetes Mellitus Treatment Adherence Clinics (DMTAC) are managed based on the in-person appointment basis. Most of the clinics are available only in specific locations. The need to travel long distance as well as long waiting hours has deterred the success of the programs. This is particularly true for the urban poor who are less likely to take time off from work than those from the higher income group. It is also noteworthy to state that the management program when available, generally target the diagnosed T2DM patients. Studies have shown that individuals with pre-diabetes can substantially reduce their risk of progression to T2DM via participation in evidence-based lifestyle change programs. Previous reports have recorded 54-58% reduction in risk for development to T2DM over 1-3 years with the protective benefit persisting up to 10 years following completion of the program. However, there are several considerations when implementing effective lifestyle intervention program among the pre-diabetes populations in Malaysia. The intervention program should easily be accessible and not confined to public primary and secondary healthcare centres which are already suffering from an overcapacity. Furthermore, consultation should be provided by properly trained healthcare professionals while the ease of communication between the patients and the "lifestyle coach" should be made available. The advancement of information technology coupled with the increasing availability and acceptance of internet and mobile devices provide useful opportunities for application of wireless and mobile technology in order to enhance self-management of chronic conditions. The incorporation of digital technologies can improve patient adherence and facilitate real-time monitoring of vital biological measurements (i.e. via wearable). Additionally, the "mobile health" (mHealth) services are easily scalable, thus providing opportunities to a greater public accessibility and narrow the disparity in access to disease management. In this study, the investigators propose to pilot a digital health supported pre-diabetes management program based in an urban community pharmacy setting

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
PreDiabetes
Keywords
digital health, mobile health, lifestyle program

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Masking Description
Cluster randomisation with blinding of statisticians
Allocation
Randomized
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intervention arm
Arm Type
Experimental
Arm Description
Participants receiving the phone app together with a fitness tracker. All participants will receive the educational curriculum through the app over a period of 24 weeks. The mobile app allows secure patient monitoring through a participant dashboard that the coach can use to increase patient adherence and motivation to achieve goals. The participants can use the app to log their food intake, weight, steps, exercise, in addition to participating in the peer support via the chat function. Participants will also receive regular care and follow up in community pharmacies for support.
Arm Title
Usual care arm
Arm Type
Active Comparator
Arm Description
The control group will be a "usual care" condition in which participants are free to seek any assistance for their medical care during the study period. Participants will be given physical tracking sheets to record their food intake, weight, steps and exercises.
Intervention Type
Behavioral
Intervention Name(s)
Mobile health
Intervention Description
Participants will be issued a fitness tracker, Bluetooth enabled glucometer, and a custom developed app which they can communicate digitally to the study investigators either as a group or individually. In the beginning of the study, participants will be taught on how to use the program, how to interact with their coach, and the importance of maintaining motivation throughout the program. Participants will have access to a pharmacist-participant messaging, group messaging, daily challenges for behavior change, education articles (biweekly bite-sized content over 24 weeks), food logging, steps and exercise logging, and feedback. They will be asked to log their weight, meals, and physical activity within the program on a weekly basis. Pharmacist will monitor participant progress through a web-based dashboard. Community pharmacist will be assisting users in setting specific, measurable, attainable, realistic, and time-based goals on a weekly basis.
Intervention Type
Behavioral
Intervention Name(s)
Usual care
Intervention Description
Participants will be issued a fitness tracker and Bluetooth enabled glucometer but these functions will not be enabled or linked to any app. All participants will be given physical tracking sheets to log in their food intake, blood glucose levels and food diary but will not have access to a personal coaching. Participants are free to seek any assistance for their medical care during the study period.
Primary Outcome Measure Information:
Title
Change in body weight
Description
Weight Loss by % of change and total weight change (kg)
Time Frame
Baseline, 1 month, 3 months, 6 months, 12 months
Secondary Outcome Measure Information:
Title
Incidence of diabetes
Description
Number of participants who develop diabetes after 12 months
Time Frame
12 months
Title
Change in hemoglobin A1c
Description
Haemoglobin A1c measured during follow-up appointments
Time Frame
Baseline, 3 months, 6 months, 12 months
Title
Change in health related quality of life
Description
EuroQol (EQ-5D-5L) to assess quality of life, with higher scores indicating better quality of life. Hospital Anxiety Depression Scale, Perceived Stress Scale and Brief Illness Perception Questionnaire to access mood and mental health.
Time Frame
Baseline, 1 month, 3 months, 6 months, 12 months
Title
Change in dietary practice
Description
3-day diet recall to assess changes in food intake
Time Frame
Baseline, 1 month, 3 months, 6 months, 12 months
Title
Change in physical activity
Description
Physical Activity Questionnaire (short form) (IPAQ) to obtain internationally comparable data on health-related physical activity
Time Frame
Baseline, 1 month, 3 months, 6 months, 12 months
Title
Change in cardiovascular risks
Description
Blood pressure and lipid profile will be collected to assess cardiovascular risks.
Time Frame
Baseline, 1 month, 3 months, 6 months, 12 months
Title
Change in anthropometry measures
Description
Body fat composition in % change, and change in waist-to-hip ratio.
Time Frame
Baseline, 1 month, 3 months, 6 months, 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged 18 years and above BMI 23 and above HbA1c 5.7 - 6.4% or FPG 5.6mmol/L - 6.9mmol/L Exclusion Criteria: Unable to give informed consent Pregnant or lactating Established diabetes Terminal illness Does not own a mobile phone Plans to relocate to an area or travel plans that do not permit full participation in the study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Chun Wie Chong, PhD
Phone
0355146688
Email
chong.chun.wie@monash.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Shaun Lee, PhD
Phone
0355145890
Email
shaun.lee@monash.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shaun Lee
Organizational Affiliation
Monash University Malaysia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Chun Wie Chong
Organizational Affiliation
Monash University Malaysia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Shaun Lee
City
Subang Jaya
State/Province
Selangor
ZIP/Postal Code
47500
Country
Malaysia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shaun Lee
Email
shaun.lee@monash.edu

12. IPD Sharing Statement

Plan to Share IPD
Undecided
IPD Sharing Plan Description
We plan to share any related individual participant data within reasonable request which can be obtained from the principal investigators

Learn more about this trial

Prevention and Treatment of Diabetes in Adults

We'll reach out to this number within 24 hrs